Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2023 | Updates on long-term ozanimod treatment for multiple sclerosis from the DAYBREAK study

Bruce Cree, MD, PhD, MAS, from the University of California, San Francisco, CA, provides us with an update on the DAYBREAK open-label extension study (NCT02576717) assessing the long-term efficacy of ozanimod as a multiple sclerosis (MS) treatment. This clinical trial included patients from the RADIANCE (NCT02047734) and SUNBEAM (NCT02294058) Phase III randomized, placebo-controlled studies, with the aim of further characterization of the long-term effects of ozanimod and to see if any new signals may emerge over time. The study found no new safety signals with long-term treatment. It was also noted that treatment-emergent adverse event rates decreased over time. The study also focused on hepatic issues associated with ozanimod, finding that although there were some discontinuations due to liver function abnormalities, there were no cases of drug induced liver injury and that frequent monitoring of liver functionality was not necessary. Recorded at the 9th Congress of the European Academy of Neurology (EAN) 2023 held in Budapest, Hungary.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Bruce Cree reports the following disclosures: I have received personal compensation for consulting from Alexion, Atara, Autobahn, Avotres, Biogen, Boston Pharma, EMD Serono, Gossamer Bio, Hexal/Sandoz, Horizon, Immunic AG, Neuron23, Novartis, Sanofi, Siemens and TG Therapeutics and UCSF has received research support from Genentech.